Daihan Pharmaceutical (023910) Fundamentals 2026 — P/E 5.6x, Revenue Analysis | SniperIQ
Daihan Pharmaceutical (023910) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩151.4B, trading at ₩25750.00 on the KOE. This SniperIQ fundamentals page covers Daihan Pharmaceutical's valuation (P/E 5.6x, P/B 0.5x), profitability (net margin 12.8%), revenue (₩208.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Daihan Pharmaceutical's market cap?
Daihan Pharmaceutical (023910) has a market capitalization of approximately ₩151.4B, trading at ₩25750.00 on the KOE. Market cap moves with the live share price.
What is Daihan Pharmaceutical's P/E ratio?
Daihan Pharmaceutical's trailing twelve-month P/E ratio is 5.6x, with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Daihan Pharmaceutical?
Daihan Pharmaceutical runs a net profit margin of 12.8%, a gross margin of 30.0%, and an operating margin of 14.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Daihan Pharmaceutical generate?
Daihan Pharmaceutical reported revenue of ₩208.6B for fiscal year 2025, with net income of ₩27.6B and earnings per share (EPS) of 4701. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Daihan Pharmaceutical pay a dividend?
Daihan Pharmaceutical offers a trailing dividend yield of about 3.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Daihan Pharmaceutical financially healthy?
Daihan Pharmaceutical carries a debt-to-equity ratio of 0.00x and a current ratio of 3.61x, with a market beta of 0.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Daihan Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Daihan Pharmaceutical (023910) the key facts are: market cap ₩151.4B, P/E 5.6x, revenue ₩208.6B, 52-week range 24000-32800. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Daihan Pharmaceutical's full fundamentals live
Get Daihan Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.